Daily NZX update, Tuesday, July 14, 2026
NZX 50 fell 0.8% to extend its weekly decline to 1.0%, though it is up 2.0% over a month and 7.4% over a year. Skellerup (SKL) led gainers, up 6% and lifting FY26 NPAT guidance to $64m-$65m. Ryman (RYM) reported Q1 FY27 ORA sales of 325. Smartshares ETFs were mixed.
How this was made
The 30-second read
Why it matters
The most decision-relevant items are Skellerup’s FY26 NPAT guidance upgrade and Pacific Edge’s direct-cost profitability progress update. Other items are primarily event-date confirmations (Chorus, Property for Industry) or operating-sales updates with reiterated delivery targets (Ryman).
Market read
Traders can use the guidance upgrade (Skellerup) as a near-term repricing catalyst and use the profitability progress update (Pacific Edge) to adjust cash-burn and adoption expectations, while the remaining items mainly set event timing.
What to watch
For Ryman and Pacific Edge, the article emphasizes progress metrics, but traders may need to watch whether independent living demand or US Medicare policy developments materially change the forward revenue mix.
Background
This is a daily NZX market wrap summarizing index performance, top gainers/decliners, Smartshares ETF moves, and several company announcements and confirmed reporting dates.
Ticker impact
Ryman reported Q1 FY27 ORA sales (265 resales, 60 new) and reiterated FY27 unit/bed delivery and FY29 $500m cash release progress.
Moderate positive bias into the next reporting/briefing window, with volatility tied to independent living vs serviced apartment demand.
The article provides specific Q1 ORA sales composition and reiterates delivery targets, which are actionable for valuation and positioning, though it is not a full earnings print.
Pacific Edge said APAC operations are moving toward direct-cost profitability, with Q1 FY27 APAC commercial tests up 12.9% and cash burn $0.17m.
Mild positive bias as traders price in reduced burn and improved adoption, with follow-through dependent on further updates.
The update includes multiple operational metrics and a refreshed US commercial strategy, but it is not a full financial statement.
Market effects
The wrap highlights mixed performance across NZX constituents, but the most actionable signal is earnings guidance improvement in a consumer/industrial name (Skellerup).
US demand and tariff-cost dynamics are explicitly cited for Skellerup, linking NZX earnings expectations to US macro/trade conditions.
Skellerup’s US-market demand and tariff costs provide a small read-through to global trade and FX sensitivity for NZ-listed exporters.
Counterpoint
Skellerup’s guidance raise may already be partially priced given the stock’s strong recent run, increasing the risk of post-news mean reversion before audited results.
Key entities
- issuerSkellerup Holdings
Upgraded FY26 NPAT guidance to $64m-$65m and cited US demand, NZ dairy consumables seasonality, lower US tariff costs, and weaker NZD.
- issuerRyman Healthcare
Reported Q1 FY27 ORA sales (265 resales, 60 new) and reiterated FY27 delivery and FY29 $500m cash release target progress.
- issuerPacific Edge
Reported APAC commercial test growth and improved unaudited cash burn, stating movement toward direct-cost profitability.
- issuerChorus
Confirmed FY results release date and investor briefing time for Aug 24.
- issuerProperty for Industry
Confirmed FY26 annual results release date for Aug 24.
